,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,4820 Richard Road SW,Suite 300,Calgary,AB,T3E 6L1,Canada,403-254-9252,403-256-8495,https://www.resverlogix.com,Biotechnology,Healthcare,"Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.",19,"{'maxAge': 1, 'name': 'Mr. Donald J. McCaffrey', 'title': 'Co-Founder, Chairman, Pres, CEO & Sec.', 'fiscalYear': 2022, 'totalPay': 505200, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.08,0.08,0.07,0.08,0.08,0.08,0.07,0.08,0.0,0.59132,-0.3181818,173126,173126,108420,130360,130360,0.07,0.075,0,0,18999330,0.07,0.26,0.0958,0.13455,0.0,0.0,CAD,85572352,0.0,179807158,271419008,124425,162367,1690761600,1693440000,0.0005,0.43775,0.0,1.23,-0.248,1672444800,1703980800,1688083200,-10044000,-0.04,-0.22,-13.769,TOR,EQUITY,RVX.TO,RVX.TO,RESVERLOGIX CORP.,Resverlogix Corp.,1083936600,America/Toronto,EDT,-14400000,0.07,2.0,buy,75000,0.0,-6215000,66648000,0.009,0.112,-0.45236,-10573750,-946000,0.0,0.0,0.0,USD,
1,4820 Richard Road SW,Suite 300,Calgary,AB,T3E 6L1,Canada,403-254-9252,403-256-8495,https://www.resverlogix.com,Biotechnology,Healthcare,"Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.",19,"{'maxAge': 1, 'name': 'Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV', 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'totalPay': 281800, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.08,0.08,0.07,0.08,0.08,0.08,0.07,0.08,0.0,0.59132,-0.3181818,173126,173126,108420,130360,130360,0.07,0.075,0,0,18999330,0.07,0.26,0.0958,0.13455,0.0,0.0,CAD,85572352,0.0,179807158,271419008,124425,162367,1690761600,1693440000,0.0005,0.43775,0.0,1.23,-0.248,1672444800,1703980800,1688083200,-10044000,-0.04,-0.22,-13.769,TOR,EQUITY,RVX.TO,RVX.TO,RESVERLOGIX CORP.,Resverlogix Corp.,1083936600,America/Toronto,EDT,-14400000,0.07,2.0,buy,75000,0.0,-6215000,66648000,0.009,0.112,-0.45236,-10573750,-946000,0.0,0.0,0.0,USD,
2,4820 Richard Road SW,Suite 300,Calgary,AB,T3E 6L1,Canada,403-254-9252,403-256-8495,https://www.resverlogix.com,Biotechnology,Healthcare,"Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.",19,"{'maxAge': 1, 'name': 'Dr. Ewelina  Kulikowski Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'totalPay': 250000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.08,0.08,0.07,0.08,0.08,0.08,0.07,0.08,0.0,0.59132,-0.3181818,173126,173126,108420,130360,130360,0.07,0.075,0,0,18999330,0.07,0.26,0.0958,0.13455,0.0,0.0,CAD,85572352,0.0,179807158,271419008,124425,162367,1690761600,1693440000,0.0005,0.43775,0.0,1.23,-0.248,1672444800,1703980800,1688083200,-10044000,-0.04,-0.22,-13.769,TOR,EQUITY,RVX.TO,RVX.TO,RESVERLOGIX CORP.,Resverlogix Corp.,1083936600,America/Toronto,EDT,-14400000,0.07,2.0,buy,75000,0.0,-6215000,66648000,0.009,0.112,-0.45236,-10573750,-946000,0.0,0.0,0.0,USD,
3,4820 Richard Road SW,Suite 300,Calgary,AB,T3E 6L1,Canada,403-254-9252,403-256-8495,https://www.resverlogix.com,Biotechnology,Healthcare,"Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.",19,"{'maxAge': 1, 'name': 'Dr. Michael  Sweeney M.D.', 'age': 61, 'title': 'Sr. VP of Clinical Devel.', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 511565, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.08,0.08,0.07,0.08,0.08,0.08,0.07,0.08,0.0,0.59132,-0.3181818,173126,173126,108420,130360,130360,0.07,0.075,0,0,18999330,0.07,0.26,0.0958,0.13455,0.0,0.0,CAD,85572352,0.0,179807158,271419008,124425,162367,1690761600,1693440000,0.0005,0.43775,0.0,1.23,-0.248,1672444800,1703980800,1688083200,-10044000,-0.04,-0.22,-13.769,TOR,EQUITY,RVX.TO,RVX.TO,RESVERLOGIX CORP.,Resverlogix Corp.,1083936600,America/Toronto,EDT,-14400000,0.07,2.0,buy,75000,0.0,-6215000,66648000,0.009,0.112,-0.45236,-10573750,-946000,0.0,0.0,0.0,USD,
4,4820 Richard Road SW,Suite 300,Calgary,AB,T3E 6L1,Canada,403-254-9252,403-256-8495,https://www.resverlogix.com,Biotechnology,Healthcare,"Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.",19,"{'maxAge': 1, 'name': 'Sarah  Zapotichny', 'title': 'Director of Investor Relations & Corp. Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,4,0.08,0.08,0.07,0.08,0.08,0.08,0.07,0.08,0.0,0.59132,-0.3181818,173126,173126,108420,130360,130360,0.07,0.075,0,0,18999330,0.07,0.26,0.0958,0.13455,0.0,0.0,CAD,85572352,0.0,179807158,271419008,124425,162367,1690761600,1693440000,0.0005,0.43775,0.0,1.23,-0.248,1672444800,1703980800,1688083200,-10044000,-0.04,-0.22,-13.769,TOR,EQUITY,RVX.TO,RVX.TO,RESVERLOGIX CORP.,Resverlogix Corp.,1083936600,America/Toronto,EDT,-14400000,0.07,2.0,buy,75000,0.0,-6215000,66648000,0.009,0.112,-0.45236,-10573750,-946000,0.0,0.0,0.0,USD,
